NCT04079582View on ClinicalTrials.gov

Outcomes of a Higher vs. Lower Hemodialysate Magnesium Concentration (Dial-Mag Canada)

NAActive, not recruitingINTERVENTIONAL
Enrollment

25,000

Participants

Timeline

Start Date

April 4, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Kidney DiseasesEnd-Stage Kidney DiseaseHemodialysis
Interventions
OTHER

Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L).

(Dialysate magnesium concentration currently used in Canada and the United States)

OTHER

Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).

(Dialysate magnesium concentration currently used in Canada and the United States)

Trial Locations (1)

N6A5W9

London Health Sciences Centre, London

All Listed Sponsors
collaborator

ICES

INDUSTRY

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER